Naltrexone Alteration of the Nicotine-Induced EEG and Mood Activation Response in Tobacco-Deprived Cigarette Smokers

Experimental and Clinical Psychopharmacology

Volumn 15, Issue 4, 2007, Pages 368-381

  Knott, Verner J ^a   Fisher, Derek J ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CARLETON UNIVERSITY   (Canada)

Author keywords

arousal; electroencephalography; mood; naltrexone; nicotine

Indexed keywords

NALTREXONE; NICOTINE; NICOTINE GUM; PLACEBO;

ADULT; ALERTNESS; ALPHA RHYTHM; AROUSAL; ARTICLE; BETA RHYTHM; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELTA RHYTHM; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; EUPHORIA; FEMALE; HUMAN; MALE; MOOD; NEUROTRANSMISSION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; THETA RHYTHM; TOBACCO; WITHDRAWAL SYNDROME;

ADULT; AFFECT; ANALYSIS OF VARIANCE; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NICOTINE; NICOTINIC AGONISTS; QUESTIONNAIRES; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 34548859569     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.15.4.368     Document Type: Article

References (133)

1. Aceto M., Scates S., and Bowman E. Nicotine's opioid and anti-opioid interactions: Proposed role in smoking behavior. European Journal of Pharmacology and Toxicology, Pharmacology Section 248 (1993) 333-335
2. Almeida L., Pereira E., Alkondon M., Fawcett W., Randall W., and Albuquerque E. The opioid antagonist naltrexone inhibits activity and alters expression of alpha 7 and alpha 4 beta2 nicotinic receptors in hippocampal neurons: Implications for smoking cessation programs. Neuropharmacology 39 (2000) 2740-2755
3. Basar E., and Schurmann M. Functional correlates of alphas. Panel discussion of the conference "Alpha Processes in the Brain.". International Journal of Psychophysiology 26 (1997) 455-474
4. Basar F., Schurmann M., Basar-Eroglu C., and Karakas S. Alpha oscillations in brain functioning: An integrative theory. International Journal of Psychophysiology 26 (1997) 5-29
5. Bechara A., Nader K., and van der Kooy D. A two-separate-motivational-systems hypothesis of opioid addiction. Pharmacology Biochemistry and Behavior 59 (1998) 1-17
6. Benowitz N., and Hatsukami D. Gender differences in the pharmacology of nicotine addiction. Addiction Biology 3 (1998) 338-404
7. Biala G., Budzynska B., and Kruk M. Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice. Pharmacological Reports 6 (2005) 755-760
8. Bond A., and Lader M. The use of analogue scale in rating subjective feelings. British Journal of Medical Psychology 47 (1974) 211-218
9. Boyudijeva N., and Sarkaf D. The secretory response of hypothalamic β-endorphin neurons to acute and chronic nicotine treatments following nicotine withdrawal. Life Sciences 61 (1997) P259-P266
10. Brandon T., and Baker T. The Smoking Consequences Questionnaire. The subjective expected utility of smoking in college students. Psychological Assessment 3 (1991) 484-491
11. Brauer L., Behm F., Westman G., Patel P., and Rose J. Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology 143 (1999) 339-346
12. Cesselin F. Opioid and anti-opioid peptides. Fundamentals of Clinical Pharmacology 9 (1995) 409-433
13. Church R. Smoking and the human EEG. In: Ney T., and Gale A. (Eds). Smoking and human behavior (1989), Wiley, Chichester, England 115-140
14. Clarke P. The central pharmacology of nicotine: Electrophysiological approaches. In: Wonacott S., Russell M., and Stolerman J. (Eds). Nicotine pharmacology: Molecular, cellular and behavioral aspects (1990), Oxford Science, Oxford, England 159-193
15. Corrigall W., and Coen K. Opiate antagonists reduce cocaine but not nicotine self-administration. Psychopharmacology 104 (1991) 167-170
16. Corrigall W., Coen K., Adamson K., Chow B., and Zhang J. Response of nicotine self-administration in the rat to manipulations of mu-opioid and γ-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology 149 (2000) 107-114
17. Corrigall W., Herling S., and Coen K. Evidence for opioid mechanisms in the behavioral effects of nicotine. Psychopharmacology 96 (1988) 29-35
18. Davenport K., Houdi A., and Van Loon G. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: Evidence for nicotine-induced release of endogenous opioid. Neuroscience Letters 113 (1990) 40-46
19. David S., Lancaster T., and Stead L. Opioid antagonists for smoking cessation. Cochrane Database of Systematic Reviews 3 (2001) CD003086
20. Davidson R. Cerebral asymmetry, emotion and affective style. In: Davidson R., and Hugdalh R. (Eds). Brain asymmetry (1995), MIT Press, Cambridge, MA 361-387
21. Delfino R., Jamner L., and Whalen C. Temporal analysis of the relationship of smoking behavior and urges to mood states in men versus women. Nicotine & Tobacco Research 3 (2001) 235-248
22. De Vries T., and Shippenberg T. Neural systems underlying opiate addiction. Journal of Neuroscience 22 (2002) 3321-3325
23. Domino E. Nicotine and tobacco dependence; normalization or stimulation?. Alcohol 24 (2001) 83-86
24. Domino E., and Matsuoka S. Effects of tobacco smoking on the topographic EEG: I. Progress in Neuro-Psychopharmacology & Biological Psychiatry 18 (1994) 879-889
25. Domino E., Riskalla M., Zhang Y., and Kim E. Effects of tobacco smoking on the topographic EEG: II. Progress in Neuro-Psychopharmacology & Biological Psychiatry 16 (1992) 462-483
26. Epstein A., and King A. Naltrexone attenuates acute cigarette smoking behavior. Pharmacology Biochemistry and Behavior 77 (2004) 29-37
27. Flores C., Hulihan-Giblin B., and Kellar K. Naltrexone blocks nicotine-induced prolactin release. Neuropharmacology 28 (1989) 1287-1290
28. Foulds J., McSorley K., Sneddon J., Feyerabend C., Jarvis M., and Russell M. Effect of subcutaneous nicotine injections on EEG alpha frequency in non-smokers: A placebo-controlled pilot study. Psychopharmacology 115 (1994) 163-166
29. Ga Y., Marquis K., Paquette N., Gussio R., and Khazan N. Haloperidol pretreatment unmasks the kappa opioid affects of U-50, 488H on cortical EEG and EEG power spectra in rats. Neuropharmacology 28 (1989) 881-884
30. Galeote L., Kieffer B., Maldonado R., and Berrendero F. Mu-opioid receptors are involved in the tolerance to nicotine antinociception. Journal of Neurochemistry 97 (2006) 416-423
31. Gil Z., Connors B., and Amitai Y. Differential regulation of neocortical synapses by neuromodulators and activity. Neuron 19 (1997) 679-686
32. Gilbert D. Depression, smoking and nicotine: Towards a brain formational situation by trait model. Drug Development Research 28 (1996) 266-277
33. Gilbert D., and Gilbert B. Nicotine and the Situation x Trait adaptive response (STAR) model: Emotional states and information processing. In: Snel J., and Lorist M. (Eds). Nicotine, caffeine and social drinking: Behavior and brain function (1998), Harwood Academic Press, London, England 131-149
34. Gilbert D., McClernon F., Rabinovich N., Dibb W., Plath L., Hiyane S., et al. EEG, physiology, and task-related mood fail to resolve across 32 days of smoking abstinence: Relations to depressive traits, nicotine exposure, and dependence. Experimental and Clinical Psychopharmacology 7 (1999) 427-443
35. Gilbert D., Meliska C., Wesler R., and Estes S. Depression, personality and gender influence EEG, cortisol, beta-endorphin, heart rate and subjective responses to smoking multiple cigarettes. Personality and Individual Differences 16 (1994) 247-264
36. Gilbert D., Sharpe P., Ramanaiah N., Detweiler F., and Anderson A. Development of a Situation x Trait adaptive response (STAR) model-based smoking motivations questionnaire. Personality and Individual Differences 29 (2000) 65-84
37. Gioanni Y., Rougeot C., Clarke P., Lepouse C., Thierry A., and Vidal C. Nicotinic receptors in the rat prefrontal cortex: Increase in glutamate release and facilitation of mediodorsal thalamocortical transmission. European Journal of Neuroscience 11 (1999) 18-30
38. Gorelick D., Rose J., and Jarvik M. Effect of naloxone on cigarette smoking. Journal of Substance Abuse 1 (1989) 153-159
39. Grasing K., and Szeto H. Naloxone causes a dose-dependent increase in total power and delta wave activity in the EEG of opioid-nerve rats. Journal of Pharmacology and Experimental Therapeutics 259 (1991) 464-469
40. Haertzen C., and Hickey J. Addiction research inventory (ARCI): Measurement of euphoria and other drug effects. In: Bozarth M. (Ed). Methods of assessing the reinforcing properties of abused drugs (1987), Springer, New York 489-524
41. Hatsukami D., Gust S., and Keenan R. Physiologic and subjective changes from smoking tobacco withdrawal. Clinical Pharmacology and Therapeutics 41 (1987) 103-107
42. Heatherton T., Kozlowski L., Frecker R., and Fagerstrom K. The Fagerstrom Test for Nicotine Dependence: A revision. British Journal of Addiction 86 (1991) 1119-1127
43. Hendriks P., Ditre J., Drobes D., and Brandon T. The early time course of smoking withdrawal effects. Psychopharmacology 187 (2006) 385-396
44. Henry J. Role of circulating opioids in the modulation of pain. Annals of the New York Academy of Sciences 467 (1986) 169-181
45. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology 129 (1997) 99-111
46. Houdi A., Pierzchala K., Palkovits M., and Van Loon G. Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 12 (1999) 161-166
47. Hughes J., and Hatsukami D. Signs and symptoms of tobacco withdrawal. Archives of General Psychiatry 43 (1986) 289-294
48. Hughes J., Hatsukami D., Pickens R., Krahn O., Malin S., and Luknic A. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 83 (1984) 82-87
49. Hukkanen J., Jacob P., and Benowitz N. Metabolism: Clinical and experimental and disposition kinetics of nicotine. Pharmacology Review 37 (2005) 79-115
50. Hutchison K., Monti P., Rohsenow D., Swift R., Colby S., Gnys M., et al. Effects of naltrexone with nicotine replacement on smoking cue reactivity: Preliminary results. Psychopharmacology 142 (1999) 139-143
51. Ikard F., and Tomkins S. The experience of affect as a determinant of smoking behavior: A series of validity studies. Journal of Abnormal Psychology 81 (1973) 172-181
52. Ise Y., Narita M., Nagase H., and Suzuki T. Modulation of kappa-opioidergic systems on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Neuroscience Letters 323 (2002) 164-166
53. Ismail A., and el-Guebaly M. Nicotine and endogenous opioids: Towards specific pharmacotherapy. Canadian Journal of Psychiatry 43 (1998) 37-42
54. Kalman D. The subjective effects of nicotine: Methodological issues, a review of experimental studies, and recommendations for future research. Nicotine & Tobacco Research 4 (2002) 25-70
55. Kalman D., and Smith S. Does nicotine do what we think it does? A meta-analytic review of the subjective effects of nicotine in nasal spray and intravenous studies with smokers and nonsmokers. Nicotine & Tobacco Research 7 (2005) 317-333
56. Karras A., and Kane J. Naloxone reduces cigarette smoking. Life Sciences 27 (1980) 1541-1545
57. Kaydoya C., Domino E., and Matsuoka S. Relationship of electroencephalographic and cardiovascular changes to plasma nicotine levels in tobacco smokers. Clinical Pharmacology Therapeutics 55 (1994) 370-377
58. Kenny P., and Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacology Biochemistry and Behavior 70 (2001) 531-549
59. Keselman H. Testing treatment effects in repeated measure designs: An update for psychophysiological researchers. Psychophysiology 35 (1998) 470-478
60. King A., de Wit H., Riley R., Dingcai C., Niauru R., and Hatsukami D. Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences. Nicotine & Tobacco Research 8 (2006) 671-682
61. King A., and Meyer P. Naltrexone alteration of acute smoking in nicotine-dependent smokers. Pharmacology Biochemistry and Behavior 66 (2000) 363-372
62. Klimesch W. Memory processes, brain oscillations and EEG synchronization. International Journal of Psychophysiology 26 (1996) 61-100
63. Klimesch W., Schimke H., Ladurner G., and Pfurtscheller G. Alpha frequency and memory performance. Psychophysiology 4 (1990) 381-396
64. Klimesch W., Schimke H., and Pfurtscheller G. Alpha frequency, cognitive load and memory performance. Brain Topography 5 (1993) 241-251
65. Knott V. Dynamic EEG changes during cigarette smoking. Neuropsychobiology 19 (1988) 54-60
66. Knott V. Brain electrical imaging the dose-response effects of cigarette smoking. Neuropsychobiology 22 (1989) 236-242
67. Knott V. Effects of low-yield cigarettes on electroencephalographic dynamics. Neuropsychobiology 21 (1989) 216-222
68. Knott V. Neuroelectric approach to the assessment of psychoactivity in comparative substance use. In: Warburton D. (Ed). Addiction controversies (1990), Harwood Academic, Churchill, Switzerland 66-89
69. Knott V. Neurophysiological aspects of smoking behavior: A neuroelectric perspective. British Journal of Addiction 86 (1991) 511-515
70. Knott V. Smoking-induced EEG alterations in brain electric activity: Normalization or enhancement?. In: Clarke P., and Sydenham B. (Eds). Effects of nicotine on biological systems 2 (1995), Birkhauser-Verlag, Basel, Switzerland 181-187
71. Knott V. Neuroelectrophysiological investigations into the smoking habit. Human Psychopharmacology 12 (1997) S69-S78
72. Knott V. Quantitative EEG methods and measures in human psychopharmacological research. Human Psychopharmacology 15 (2000) 479-498
73. Knott V. Electroencephalographic characterization of cigarette smoking behavior. Alcohol 24 (2001) 95-97
74. Knott V., Bosman M., Mahoney C., Ilivitsky V., and Quirt K. Transdermal nicotine: Single dose effects on mood, EEG, performance, and event-related potentials. Pharmacology Biochemistry and Behavior 63 (1999) 253-261
75. Knott V., and Harr A. Functional utility of nicotine: Arousal, mood and performance. In: Snell J., and Lorist M. (Eds). Nicotine, caffeine and social drinking: Behavior and brain function (1998), Harwood Academic Publishers, Amsterdam, the Netherlands 115-130
76. Knott V., Harr A., Ilivitsky V., and Mahoney C. The cholinergic basis of the smoking-induced EEG activation profile. Neuropsychobiology 38 (1998) 97-102
77. Knott V., Hooper C., Lusk-Mikkelsen S., and Kerr C. Variations in spontaneous brain electrical (EEG) topography related to cigarette smoking: Acute smoking, cholinergic transmission, individual differences and psychopathology. In: Domino E. (Ed). Brain imaging of nicotine and tobacco smoking (1995), NPP Books, Ann Arbor, MI 167-189
78. Knott V., McIntosh J., Millar A., Fisher D., Villeneuve D., Ilivitsky V., and Horn E. Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist. Pharmacology Biochemistry and Behavior 85 (2006) 228-242
79. Knott V., Raegele M., Fisher D., Robertson N., Millar A., McIntosh J., and Ilivitsky V. Clonidine pre-treatment fails to block acute smoking-induced EEG arousal/mood in cigarette smokers. Pharmacology Biochemistry and Behavior 80 (2005) 161-171
80. Kogan M., Verebey K., and Mule S. Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. Research Communications in Chemistry, Pathology and Pharmacology 18 (1977) 29-34
81. Konopacki J., Bland B., and Roth S. Evidence that activation of in vitro hippocampal rhythm only involves muscarinic receptors. Brain Research 455 (1988) 110-114
82. Krishnan-Sarin S., Rosen M., and O'Malley S. Naloxone challenge in smokers: Preliminary evidence of an opioid component in nicotine dependence. Archives of General Psychiatry 56 (1999) 663-668
83. Lambe E., Picciotto M., and Aghajanian C. Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 28 (2003) 216-225
84. Lindgren M., Molander L., Verbaan C., Lunell E., and Rosen I. Electroencephalographic effects of intravenous nicotine: A dose-response study. Psychopharmacology 145 (1999) 342-350
85. Malin D., Lake J., Carter V., Cunningham J., and Wilson O. Naloxone precipitates nicotine abstinence syndrome. Psychopharmacology 112 (1993) 339-342
86. Malin D., Lake J., Payne M., Short P., Carter V., Cunningham J., and Wilson O. Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible. Pharmacology Biochemistry and Behavior 53 (1996) 81-85
87. Mansvelder H., van Aerde K., Couey J., and Brussaard A. Nicotinic modulation of neuronal networks: From receptors to cognition. Psychopharmacology 184 (2006) 292-305
88. Meyer M., Straughn A., Lo M., Schary W., and Whitney C. Bioequivalence, dose-proportionality and pharmacokinetics of naltrexone after oral administration. Journal of Clinical Psychiatry 45 (1984) 15-19
89. Mougey E., and Meyerhoff J. Effects of cholinomimetics and cholinesterase inhibitors on plasma beta-endorphins. Abstract of the Society of Neuroscience, 81 7 (1981) 135
90. Nemeth-Coslett K., and Griffiths R. Naloxone does not affect cigarette smoking. Psychopharmacology 89 (1986) 261-264
91. Newton T., Cook J., Holschneider D., Rosenblatt M., Lindholm J., and Jarvik M. Quantitative EEG effects of nicotine replacement by cigarette smoking. Neuropsychobiology 37 (1998) 112-116
92. O'Malley S., Krishnan-Sarin S., and Rounsaville B. Naltrexone. In: Sadock B., and Sadock V. (Eds). Comprehensive textbook of psychiatry. 7th ed. 2 (2000), Lippincott, Williams & Wilkins, New York 2407-2412
93. Opitz K., and Weischer M. Volitional oral intake of nicotine in tupaias: Drug-induced alterations. Drug and Alcohol Dependence 21 (1988) 99-109
94. Paquette N., and Young G. Relationship between regulation of morphine-induced EEG effects and changes in naloxone sensitivity. European Journal of Pharmacology 196 (1991) 61-67
95. Perkins K. Sex differences in nicotine versus nonnicotine reinforcement as determinants of tobacco smoking. Experimental and Clinical Psychopharmacology 4 (1996) 166-177
96. Perkins K., Donny E., and Caggiula A. Sex differences in nicotine effects and self-administration: Review of human and animal evidence. Nicotine and Tobacco Research 1 (1998) 301-315
97. Perugini M., Mahoney C., Ilivitsky V., Young S., and Knott V. Effects of acute tryptophan depletion on acute smoking abstinence symptoms on the acute smoking response. Pharmacology Biochemistry and Behavior 74 (2003) 513-522
98. Peterson J., Conrod R., Vassileva J., Gianoulakis E., and Pihl R. Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication. Journal of Psychiatry and Neuroscience 31 (2006) 386-393
99. Petsche H., Kaplan S., von Stein A., and Filz O. The possible meaning of the upper and lower alpha frequency ranges for cognitive and creative tasks. International Journal of Psychophysiology 26 (1997) 77-97
100. Pickworth W., Fant R., Nelson R., Rohrer M., and Henningfield J. Pharmacodynamic effects of new de-nicotinized cigarettes. Nicotine & Tobacco Research 1 (1999) 357-364
101. Pickworth W., Herning R., and Henningfield J. Electroencephalographic effects of nicotine chewing gum in humans. Pharmacology Biochemistry and Behavior 25 (1986) 879-882
102. Pickworth W., Herning R., and Henningfield J. Mecamylamine reduces some EEG effects of nicotine chewing gum in humans. Pharmacology Biochemistry and Behavior 30 (1988) 149-153
103. Pickworth W., Herning R., and Henningfield J. Spontaneous EEG changes during tobacco abstinence and nicotine substitution in human volunteers. Journal of Pharmacology and Experimental Therapeutics 22 (1989) 976-982
104. Pickworth W., O'Hare E., Fant R., and Moolchan E. EEG effects of conventional and denicotinized cigarettes in a spaced smoking paradigm. Brain and Cognition 53 (2003) 75-81
105. Picton T., Bentin S., Berg P., Douchin E., Hillyard S., Johnson Jr. R., et al. Guidelines for the recording and quantitative analysis of electroencephalographic activity in research contexts. Psychophysiology 30 (2000) 547-558
106. Pierzchala K., Houdi A., and Van Loon G. Nicotine-induced alterations in brain regional concentrations of native and cryptic met- and lev-enkephalin. Peptides 8 (1987) 1035-1043
107. Pomerleau O. Endogenous opioids and smoking: A review of progress and problems. Psychoneuroendocrinology 23 (1998) 115-130
108. Pomerleau O., Fertig J., Seyler L., and Jaffe J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology 81 (1983) 61-67
109. Pomerleau O., and Pomerleau C. Neuroregulators and the reinforcement of smoking: Towards a biobehavioral explanation. Neuroscience & Biobehavioral Reviews 8 (1984) 503-513
110. Pomerleau O., and Rosencranz J. Neuroregulatory effects of nicotine. Psychoneuroendocrinology 14 (1989) 407-423
111. Pritchard W., Houlihan M., Guy T., and Robinson J. Little evidence that "denicotinized" menthol cigarettes have pharmacological effects: An EEG/heart-rate/subjective-response study. Psychopharmacology 143 (1999) 273-279
112. Rezayof A., Zatali H., Haeri-Rohani A., and Zarrindast M.-R. Dorsal hippocampal muscarinic and nicotinic receptors are involved in mediating morphine reward. Behavioural Brain Research 166 (2006) 281-290
113. Roozen H., Van Beers S., Weevers H., Beteler M., Willemsen M., Postmus P., and Kerkhof A. Effects on smoking cessation: Naltrexone combined with a cognitive behavioral treatment based on the community reinforcement approach. Substance Use and Misuse 41 (2006) 45-60
114. Rukstalis M., Jepson C., Strasser A., Lynch A., Perkins K., Patterson F., and Lerman C. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology 180 (2005) 41-48
115. Rukstalis M., Stromberg M., O'Brien C., and Volpicelli J. 6-beta-naltrexol reduces alcohol consumption in rats. Alcohol Clinical and Experimental Research 24 (2000) 1593-1596
116. Russell M., Peto J., and Patel U. The classification of smoking by factorial structure of motives. Journal of the Royal Statistical Society 137 (1974) 313-346
117. Shikata H., Fukai H., Ohya I., and Sakaki T. Characterization of topographic EEG changes when smoking a cigarette. Psychopharmacology 119 (1995) 361-367
118. Tempel, A., & Zukin, R. (1987). Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro radiograph. Proceedings of the National Academy of Sciences, 84, 4308-4312.
119. Terenius L. Opioid peptides, pain and stress. Progress in Brain Research 92 (1992) 375-383
120. Teter C., Asfaw B., Lisong N., Lutz M., Domino E., and Guthrie S. Comparative effects of tobacco smoking and nasal nicotine. European Journal of Pharmacology 58 (2002) 309-314
121. Tien L., Fan L., Sogawa C., Ma T., Loh H., and Ho J. Changes in acetylcholinesterase activity and muscarinic receptor bindings in mu-opioid knockout mice. Brain Research and Molecular Brain Research 126 (2004) 38-44
122. Tome A., Izaquirre V., Rosario L., Cena V., and Gonzales-Garcia G. Naloxone inhibits nicotine-induced receptor current and catecholamine secretion in bovine chromafin cells. Brain Research 903 (2001) 62-65
123. Verebey K., Volavka J., Mule S., and Resnick R. Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing. Clinical Pharmacology & Therapeutics 20 (1976) 315-328
124. Vidal C., and Changeux J. Nicotinic and muscarinic modulating of excitatory synaptic transmission in the rat prefrontal cortex in vitro. Neuroscience 56 (1993) 23-32
125. Volavka J., James B., Reker D., Mallya A., Cho D., and Revnick J. EEG and other effects of naltrexone and heroin in man. Pharmakopsychiatrie & Neuropsychopharmakologie 12 (1979) 79-85
126. Waldron I. Patterns and causes of gender differences in smoking. Social Science Medicine 32 (1991) 989-1005
127. Walker D., Mahoney C., Ilivitsky V., and Knott V. Effects of haloperidol pretreatment on the smoking-induced EEG/mood activation response profile. Neuropsychobiology 43 (2001) 102-112
128. Wall M., Brine D., and Perez-Reyes M. The metabolism of naltrexone in man. National Institute of Drug Abuse Research Monograph 28 (1981) 105-131
129. Waters A., and Sutton S. Direct and indirect effects of nicotine/smoking on cognitions in humans. Addictive Behavior 25 (2000) 29-43
130. Watkins S., Koob G., and Markou A. Neural mechanisms underlying nicotine addiction: Acute positive reinforcement and withdrawal. Nicotine & Tobacco Research 2 (2000) 19-32
131. Wewers M., Dhatt R., and Tejwani G. Naltrexone administration affects and lithium smoking behavior. Psychopharmacology 140 (1998) 185-190
132. Xu X., and Domino F. Effects of tobacco smoking on topographic EEG and Stroop test in smoking deprived smokers. Progress in Neuron-Psychopharmacology & Biological Psychiatry 24 (2000) 535-546
133. Young C., and Khazan N. Differential neuropharmacological effects of mu, kappa and sigma opioid agonists on cortical EEG power spectra in the rat. Neuropharmacology 23 (1984) 1161-1165